You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Article metrics

Article menu
Clinical trials monitor
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

 

Online download statistics by month:

Online download statistics by month: February 2022 to July 2025

AbstractFullPdf
Feb 2022909935226
Mar 202243344299
Apr 202222023066
May 202216016764
Jun 202214415450
Jul 202229630247
Aug 202242042464
Sep 202216717469
Oct 202216216970
Nov 202213613765
Dec 202210610540
Jan 202311311335
Feb 202312312342
Mar 2023878731
Apr 2023828254
May 2023787845
Jun 2023525328
Jul 2023848748
Aug 2023656826
Sep 2023848446
Oct 2023838345
Nov 2023868627
Dec 2023686940
Jan 2024606036
Feb 2024848851
Mar 20249910081
Apr 2024807945
May 2024808137
Jun 2024727233
Jul 202411211255
Aug 2024838175
Sep 2024676736
Oct 2024747738
Nov 2024818540
Dec 202410110342
Jan 2025697136
Feb 202523223454
Mar 2025878750
Apr 202513313364
May 2025818144
Jun 2025353616
Jul 2025110
Total578959002160